Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details)

v3.24.1.1.u2
Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares
Mar. 31, 2024
Mar. 31, 2023
Tyme    
Anti-dilutive securities    
Warrants issued to purchase common stock 41,085 41,085
Private Placement - December 2020    
Anti-dilutive securities    
Warrants issued to purchase common stock 282,809 282,809
Private Placement - September 2022    
Anti-dilutive securities    
Warrants issued to purchase common stock 13,813,912 13,813,912
First Draw of Loan Agreement    
Anti-dilutive securities    
Warrants issued to purchase common stock 2,754 2,754
Second Draw on Loan Agreement    
Anti-dilutive securities    
Warrants issued to purchase common stock 1,738 1,738